Visit main University website

Find MND Biomarker

Find MND Biomarker

Find MND Biomarker

Find MND Biomarker

Welcome to FindMNDBiomarker, an integrative database that consolidates the proteomic findings in brain tissue and biofluids (CSF and blood) from patients with motor neuron disease (also known as amyotrophic lateral sclerosis). FindMNDBiomarker is designed for users to quickly assess whether their proteins of interest have been identified in other cohorts and biosamples from patients with MND/ALS.

Purpose: The goal of this search platform is to facilitate the comparison and discovery of proteins that may serve as promising and reproducible biofluid biomarkers of brain-specific changes in MND/ALS and to identify markers that should be further targeted for analyses and validation.

Using this database: Searches can be performed by entering the protein UniProt IDs, names and sample types into the relevant search term box using free text entry. For example, entering ‘NEFL’ will generate a list of all publications in which NEFL was identified to be significantly dysregulated.

A searchable and filterable table is provided with the following columns:

  • Name: Gene name corresponding to the UniProt ID
  • UniProt ID: UniProt accession number
  • Publication: Study Reference
  • Condition: e.g.ALS – Control, ALS Fast – ALS Slow
  • Sample Type: Sample type used (Abbreviations: SMNs, single motor neurons; AH, anterior horn; PH, posterior horn)
  • Regulation: Direction of change (upregulated or downregulated)
  • Cohorts: Cohort size used for each study
  • Average age at onset ± standard deviation/age range: Average age at onset of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average age at collection ± standard deviation/age range: Average age at collection of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average PMI (range) (hours): Average postmortem interval with range (if provided by tissue studies)

To cite this database: Further details and application of this search tool are described in our manuscript “title” that can be located with this DOI: _____

Contact: For help contact rachel.tan1@sydney.edu.au
Sort by:
Total Records Found: 3275, showing 100 per page
Biomarker NameUniProt IDPublicationDisease GroupComparator GroupSample TypeRegulationCohortsAverage age at onsetAverage age at collectionAverage PMI
PDHA1 P08559 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
PDGFB P01127 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
PDGFB P01127 Berrone et al. 2023 ALS Control Plasma Up 16 ALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS) N/A
PDGFA P04085 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PDCD6IP Q8WUM4 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
PDCD6IP Q8WUM4 Hayashi et al. 2020 ALS Control CSF exosome-enriched fractions Up 3 ALS, 3 control N/A 74.3 N/A
PDCD6IP Q8WUM4 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PDCD5 O14737 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
PCSK9 Q8NBP7 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PCSK2 P16519 Vu et al. 2023 ALS fast ALS slow CSF Down 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow) N/A
PCSK1N Q9UHG2 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
PCSK1N Q9UHG2 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
PCSK1 P29120 Vu et al. 2023 ALS fast ALS slow CSF Down 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow) N/A
PCP4 P48539 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
PCP4 P48539 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PCOLCE Q15113 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PCMT1 H7BY58 Andrés-Benito et al. 2020 ALS Control CSF Up 15 ALS, 15 control N/A 61 ± 10.8 N/A
PCMT1 P22061 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PCMT1 P22061 Zhou et al. 2023 BO-ALS Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
PCMT1 P22061 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
PCMT1 P22061 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
PCLO Q9Y6V0 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
PCK2 Q16822 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
PCDHB9 Q9Y5E1 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PCDH9 Q9HC56 Zhou et al. 2023 BO-ALS Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
PCDH19 Q8TAB3 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PCDH18 Q9HCL0 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PCDH10 Q9P2E7 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PCDH1 Q08174 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
PCCB P05166 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
PCBP3 P57721 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
PCBP2 Q15366 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
PCBP1 Q15365 Seyfried et al. 2018 ALS Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
PCBP1 Q15365 Zubiri et al. 2018 Late ALS (ALS slow cohort) Early ALS (ALS slow cohort) Plasma Down 6 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow) N/A N/A
PCBP1 Q15365 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
PCBD2 H0YA52 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
PCBD1 P61457 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
PC P11498 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
PBXIP1 Q96AQ6 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PARP1 P09874 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
PARK7 Q99497 Filareti et al. 2017 Late ALS Early ALS PBMCs Down 16 Early-ALS, 16 Late-ALS N/A 50 ± 5 (Early-ALS), 80 ± 4 (Late-ALS) N/A
PARK7 Q99497 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
PAPLN O95428 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PAMR1 Q6UXH9 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PALLD Q8WX93 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
PALLD Q8WX93 Oeckl et al. 2020 ALS Control Spinal cord Up 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
PAK1 Q13153 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
PAICS P22234 Collins et al. 2015 ALS Control CSF Up 90 ALS, 80 control N/A N/A N/A
PAFAH1B2 P68402 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
PAFAH1B1 P43034 Seyfried et al. 2018 ALS Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
PADI2 Q9Y2J8 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
PACSIN1 Q9BY11 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
PABPC1 E7EQV3 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
PABPC1 A0A087WTT1 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
PAAF1 Q9BRP4 Andrés-Benito et al. 2020 ALS Control CSF Down 15 ALS, 15 control N/A 61 ± 10.8 N/A
PA2G4 Q9UQ80 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
P4HB P07237 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
P4HB P07237 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
P4HB P07237 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
P4HB P07237 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
OXCT1 P55809 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
OXCT1 P55809 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
OTUD7A Q8TE49 Collins et al. 2015 ALS Control CSF Up 90 ALS, 80 control N/A N/A N/A
OTUB1 F5GYN4 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
OSMR Q99650 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
OSCAR Q8IYS5 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
OSBPL3 Q9H4L5 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
ORM2 P19652 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow) N/A
ORM1 P02763 Vilardo et al. 2024 ALS (validation cohort) ALS (validation cohort) Plasma EVs Up 61 ALS, 30 control N/A 62.88 ± 12.60 N/A
ORM1 P02763 Xu et al. 2018 ALS Control Plasma Up 42 ALS, 18 control N/A 61.8 ± 9.6 N/A
ORM1 P02763 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
ORM1 P02763 Chen et al. 2016 ALS Control CSF Down 35 ALS, 10 control N/A 52.7 ±12.13 N/A
ORM1 P02763 Oeckl et al. 2020 ALS Control Spinal cord Up 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
OR51E2 Q9H255 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
OPTN Q96CV9 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
OPCML Q14982 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
OPCML Q14982 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
OMG P23515 Collins et al. 2015 ALS Control CSF Down 90 ALS, 80 control N/A N/A N/A
OMG P23515 Zhou et al. 2023 BO-ALS Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
OMG P23515 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
OMD Q99983 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
OLR1 P78380 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
OLFL3 Q9NRN5 Andrés-Benito et al. 2020 ALS Control CSF Up 15 ALS, 15 control N/A 61 ± 10.8 N/A
OGN P20774 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
OGDHL Q9ULD0 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
OGDH Q02218 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
OGDH Q02218 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
OGDH E9PFG7 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
OCIAD1 Q9NX40 Umoh et al. 2018 ALS Control Frontal cortex Down 19 ALS, 10 control 55 59 10.6
OAF Q86UD1 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
NUDT4 Q9NZJ9 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
NUDT4 Q9NZJ9 Oeckl et al. 2020 ALS Control Spinal cord Up 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
NUDT16 Q96DE0 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
NUDT16 Q96DE0 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
NUDT14 O95848 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
NUDCD3 Q8IVD9 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
NUDC Q9Y266 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
NUDC Q9Y266 Seyfried et al. 2018 ALS Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
NUCKS1 Q9H1E3 Zubiri et al. 2018 ALS fast (late stage) ALS slow (late stage) Plasma Up 6 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow) N/A N/A
NUCKS1 Q9H1E3 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A